JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Proactive Consultation by a Clinical Pathologist Prevents Diagnostic Delay in Hematological Malignancies
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Proactive Consultation by a Clinical Pathologist Prevents Diagnostic Delay in Hematological Malignancies
Chang, Chih-Chun; Su, Ming-Jang; Ho, Jung-Li; Sun, Jen-Tang; Tsai, Huang-Wen; Tang, Hui-Fei; Chu, Fang-Yeh;
  PDF(new window)
 Abstract
Background: Diagnostic difficulties in hematological malignancies may lead to unacceptably prolonged help-seeking to diagnostic interval as well as increased complications and poor outcomes. Proactive consultation by a clinical pathologist (PCCP) may help clinical diagnosis and therapeutic strategy. Hence, the aim of this investigation was to evaluate the effect of PCCP on the help-seeking to diagnostic interval in hematological cancer cases. Materials and Methods: From January to November, 2015, abnormal results of hematological laboratory testing with added laboratory comment were selectively screened out, and patients with such abnormalities in hematological laboratory testing and accompanied laboratory comment with PCCP were enrolled. Results: A total of 125 aberrant results of hematological laboratory testing were given with accompanied laboratory comments with PCCP and 40.8% (n
 Keywords
Active laboratory consultation;proactive consultation by clinical pathologist;hematological malignancies;
 Language
English
 Cited by
 References
1.
Abdel-Rahman M, Stockton D, Rachet B, et al (2009). What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable? Br J Cancer, 101, 115-24. crossref(new window)

2.
Elliss-Brookes L, McPhail S, Ives A, et al (2012). Routes to diagnosis for cancer - determining the patient journey using multiple routine data sets. Br J Cancer, 107, 1220-26. crossref(new window)

3.
Friese CR, Abel GA, Magazu LS, et al (2009). Diagnostic delay and complications for older adults with multiple myeloma. Leuk Lymphoma, 50, 392-400. crossref(new window)

4.
Howell DA, Smith AG, Roman E (2008). Help-seeking behaviour in patients with lymphoma. Eur J Cancer Care, 17, 394-403. crossref(new window)

5.
Howell DA, Smith AG, Jack A, et al (2013). Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network. BMC Hematol, 13, 9. crossref(new window)

6.
Irfan SM, Bhurgri Y (2009). Clinico-pathological features and outcomes in chronic phase chronic myeloid leukemia patients treated with hydroxyurea. Asian Pac J Cancer Prev, 10, 591-94.

7.
Kariyawasan CC, Hughes DA, Jayatillake MM, et al (2007). Multiple myeloma: causes and consequences of delay in diagnosis. QJM, 100, 635-40. crossref(new window)

8.
Kuwajima M (1997). Clinical laboratory consultation in the general hospital. Rinsho Byori, 45, 727-31.

9.
Kuwajima M (1998). Active laboratory consultation for the clinical supporting system in the general hospital. Rinsho Byori, 46, 994-8.

10.
Kyle RA, Gertz MA, Witzig TE, et al (2003). Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc, 78, 21-33. crossref(new window)

11.
Lyratzopoulos G, Neal RD, Barbiere JM, et al (2012). Variation in number of general practitioner consultations before hospital referral for cancer: findings from the 2010 national cancer patient experience survey in England. Lancet Oncol, 13, 353-65. crossref(new window)

12.
Lyratzopoulos G, Abel GA, McPhail S, et al (2013). Measures of promptness of cancer diagnosis in primary care: secondary analysis of national audit data on patients with 18 common and rarer cancers. Br J Cancer, 108, 686-90. crossref(new window)

13.
Mai Y, Qi P, Xu Y, et al (2007). Clinical and laboratory features of newly diagnosed multiple myeloma: a retrospective, single-centre analysis. Chin Med J, 120, 1727-9.

14.
Burke MD (1995). Clinical laboratory consultation. Clin Chem, 41, 1237-40.

15.
Ong F, Hermans J, Noordijk EM, et al (1995). Presenting signs and symptoms in multiple myeloma: high percentages of stage III among patients without apparent myeloma-associated symptoms. Ann Hematol, 70, 149-52 crossref(new window)

16.
Summerfield GP, Carey PJ, Galloway MJ, et al (2000). An audit of delays in diagnosis and treatment of lymphoma in district hospitals in the northern region of the United Kingdom. Clin Lab Haematol, 22, 157-60. crossref(new window)

17.
Thomson CS, Forman D (2009). Cancer survival in England and the influence of early diagnosis: what can we learn from recent EUROCARE results? Br J Cancer, 101, 102-9. crossref(new window)